 |
|
Cystatin C and Incident Peripheral Arterial Disease Events in the Elderly
Results From the Cardiovascular Health Study
Ann M. O’Hare, MD, MA;
Anne B. Newman, MD, MPH;
Ronit Katz, PhD;
Linda F. Fried, MD;
Catherine O. Stehman-Breen, MD;
Stephen L. Seliger, MD;
David S. Siscovick, MD;
Michael G. Shlipak, MD, MPH
Arch Intern Med. 2005;165:2666-2670.
Background The association of cystatin C, a novel marker of renal function, with risk for developing complications related to peripheral arterial disease (PAD) has not been examined.
Methods We evaluated the hypothesis that a high cystatin C concentration is independently associated with future PAD events among 4025 participants in the Cardiovascular Health Study who underwent serum cystatin C measurement at the 1992-1993 visit and who did not have PAD at baseline. The association of cystatin C quintiles with time to first lower-extremity PAD procedure (bypass surgery, angioplasty, or amputation) was evaluated using multivariable proportional hazards models. Secondary analyses were conducted using quintiles of serum creatinine level and estimated glomerular filtration rate (eGFR).
Results The annualized risk of undergoing a procedure for PAD was 0.43% per year among participants in the highest cystatin C quintile (>1.27 mg/L) compared with 0.21% per year or less in all other quintiles. After multivariable adjustment for known risk factors for PAD, elevated cystatin C levels remained associated with the outcome (hazard ratio, 2.5 for highest vs lowest quintile of cystatin C, 95% confidence interval, 1.2-5.1). The highest quintiles of serum creatinine level and eGFR were not associated with future PAD events in either unadjusted or adjusted analyses.
Conclusion Elevated concentrations of cystatin C were independently predictive of incident PAD events among community-dwelling elderly patients.
Author Affiliations: Nephrology Division, Department of Medicine (Dr O’Hare), and General Internal Medicine Section (Dr Shlipak), Veterans Affairs Medical Center, San Francisco, and Nephrology Division, Department of Medicine (Dr O’Hare), and Departments of Medicine and Epidemiology and Biostatistics (Dr Shlipak), University of California, San Francisco; Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, and the Division of Geriatric Medicine (Dr Newman), and the Renal-Electrolyte Division (Dr Fried), University of Pittsburgh School of Medicine, and the Renal Section, Veterans Affairs Pittsburgh Healthcare System (Dr Fried), Pittsburgh, Pa; Collaborative Health Studies Coordinating Center (Dr Katz) and Departments of Medicine (Dr Seliger) and Medicine, Epidemiology, and Health Services (Dr Siscovick), University of Washington, Seattle; and Amgen Inc, Thousand Oaks, Calif (Dr Stehman-Breen).
RELATED ARTICLE
Renal Function and Risk of Myocardial Infarction in an Elderly Population: The Rotterdam Study
Jasper J. Brugts, Annemarieke M. Knetsch, Francesco U. S. Mattace-Raso, Albert Hofman, and Jacqueline C. M. Witteman
Arch Intern Med. 2005;165(22):2659-2665.
ABSTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Symptomatic Peripheral Arterial Disease in Women: Nontraditional Biomarkers of Elevated Risk
Pradhan et al.
Circulation 2008;117:823-831.
ABSTRACT
| FULL TEXT
Alcohol Consumption and Lower Extremity Arterial Disease among Older Adults: The Cardiovascular Health Study
Mukamal et al.
Am J Epidemiol 2008;167:34-41.
ABSTRACT
| FULL TEXT
Cystatin C as a Risk Factor for Outcomes in Chronic Kidney Disease
Menon et al.
ANN INTERN MED 2007;147:19-27.
ABSTRACT
| FULL TEXT
Elevated Cystatin C Concentration and Progression to Pre-Diabetes: The Western New York Study
Donahue et al.
Diabetes Care 2007;30:1724-1729.
ABSTRACT
| FULL TEXT
Cystatin C and Prognosis for Cardiovascular and Kidney Outcomes in Elderly Persons without Chronic Kidney Disease
Shlipak et al.
ANN INTERN MED 2006;145:237-246.
ABSTRACT
| FULL TEXT
Biomarkers of Cardiovascular Disease: Molecular Basis and Practical Considerations
Vasan
Circulation 2006;113:2335-2362.
FULL TEXT
|
